[HTML][HTML] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC …
JY Lee, X Qing, W Xiumin, B Yali, S Chi, SH Bak… - Oncotarget, 2016 - ncbi.nlm.nih.gov
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
S Chi, JM Sun, SH Lee, C EK, DW Kim… - …, 2016 - scholarworks.bwise.kr
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
[引用][C] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC …
JY Lee, X Qing, W Xiumin, B Yali, S Chi, SH Bak… - Oncotarget, 2016 - cir.nii.ac.jp
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients
treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) | CiNii Research …
treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02) | CiNii Research …
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
JY Lee, X Qing, W Xiumin, B Yali, S Chi, SH Bak… - 2016 - ir.ymlib.yonsei.ac.kr
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
JY Lee, X Qing, W Xiumin, B Yali, S Chi… - …, 2016 - pubmed.ncbi.nlm.nih.gov
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
[PDF][PDF] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC …
HRK Kim, YJ Min, SH Jung, K Park, M Mao, MJ Ahn - researchgate.net
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
JY Lee, X Qing, W Xiumin, B Yali, S Chi… - …, 2016 - snucm.elsevierpure.com
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
JY Lee, X Qing, W Xiumin, B Yali, S Chi… - …, 2016 - mdanderson.elsevierpure.com
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
[PDF][PDF] Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC …
HRK Kim, YJ Min, SH Jung, K Park, M Mao, MJ Ahn - pdfs.semanticscholar.org
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
JY Lee, X Qing, W Xiumin, B Yali, S Chi, SH Bak… - Oncotarget, 2016 - europepmc.org
We hypothesized that plasma-based EGFR mutation analysis for NSCLC may be feasible for
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …
monitoring treatment response to EGFR TKIs and also predict drug resistance. Clinically …